| Spirit Technology Solutions Ltd (ST1) ORDINARY FULLY PAID |
Communication Services |
$80 |
Retail Offer Booklet and Letter to Eligible Shareholders
|
30 Aug 2024 9:35AM |
$0.056 |
$0.420 |
risen by
650%
|
|
ST1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Spirit Technology Solutions Ltd announced an acquisition of Forensic IT Solutions Pty Ltd for $7.6 million.
- The acquisition will be funded by a fully underwritten placement and entitlement offer to raise approximately $20 million.
- The entitlement offer is at $0.053 per new share with a 1 for 4.024 ratio.
- The offer includes a placement to raise $2 million and a pro-rata accelerated non-renounceable entitlement offer to raise a further $18 million.
- Retail shareholders can participate in the entitlement offer starting 30 August 2024, closing on 13 September 2024.
- The acquisition aims to complement Spirit's cyber security offerings and expand its capability in incident response.
- The offer is open to shareholders in Australia and New Zealand, among other approved jurisdictions.
- Unified Capital Partners Pty Ltd is the lead manager, underwriter, and bookrunner for the offer.
- Key employees from Forensic IT will join Spirit’s leadership team as part of the acquisition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IODM Limited (IOD) ORDINARY FULLY PAID |
Information Technology |
$74 |
IOD FY24 Results Announcement
|
30 Aug 2024 9:35AM |
$0.175 |
$0.120 |
fallen by
31.43%
|
|
IOD - Price-sensitive ASX Announcement
Full Release
Key Points
- IODM Limited (ASX: IOD) released its FY24 results for the period ended 30 June 2024.
- Group revenue increased by 63% to $2.6 million compared to the prior corresponding period.
- Receipts from customers rose by 87% to $2.1 million.
- The company experienced significant growth in the UK education sector, with revenue from this area increasing by 180.9%.
- A new revenue agreement with Convera for UK education, effective from January 2024, has positively impacted results.
- Net loss after tax for FY24 was $3.1 million, slightly higher than the previous year.
- Subsequent to the fiscal year-end, the company raised approximately $1.7 million through a share placement.
- The additional funds are aimed at accelerating the global education roll-out into North America and supporting growth initiatives in the UK.
- The company has onboarded over 20 UK universities and significantly increased collections from these institutions.
- Further investments were made in platform and technical enhancements, including the addition of a new Chief Technology Officer.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Echo IQ Limited (EIQ) ORDINARY FULLY PAID |
Information Technology |
$145 |
Trading Halt
|
30 Aug 2024 9:35AM |
$0.150 |
$0.225 |
risen by
50%
|
|
EIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- EchoIQ Limited (ASX: EIQ) requested a trading halt.
- The trading halt is pending the release of results from clinical studies.
- The trading halt is effective until the release of the announcement or the commencement of normal trading on 3 September 2024.
- The company is not aware of any reason why the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$570 |
Increased fully franked interim div, FY2024 Interim Results
|
30 Aug 2024 9:35AM |
$1.315 |
$1.425 |
risen by
8.37%
|
|
FGG - Price-sensitive ASX Announcement
Full Release
Key Points
- Future Generation Global Investment Company Limited (FGG) has announced an increased fully franked interim dividend.
- FGG reported its interim results for the fiscal year 2024.
- The company has generated strong financial performance.
- The interim dividend has been increased to 2.0 cents per share, fully franked.
- FGG focuses on achieving both social impact and strong financial returns.
- The company has delivered a positive investment performance.
- FGG continues to support Australian charities focused on children and youth at risk.
- The company's investment portfolio is diversified across global equities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tlou Energy Limited (TOU) ORDINARY FULLY PAID |
Energy |
$21 |
Notice under section 708A(5)(e) of the Corporations Act 2001
|
30 Aug 2024 9:34AM |
$0.034 |
$0.016 |
fallen by
52.94%
|
|
| Tamboran Resources Corporation (TBN) CDI 200:1 US PERSON PROHIBITED EXCLUDING QIB |
Energy |
$509 |
Commencement of Shenandoah South Pilot Project drilling
|
30 Aug 2024 9:34AM |
$0.155 |
$0.175 |
risen by
12.90%
|
|
TBN - Price-sensitive ASX Announcement
Full Release
Key Points
- Tamboran Resources Corporation has commenced the Shenandoah South Pilot Project drilling program.
- The SS-2H well in EP 98 has been spudded and is located roughly 3 miles north of the SS-1H well.
- The SS-2H and SS-3H wells will be drilled using Helmerich & Payne's super-spec FlexRig® Flex 3 rig targeting the Middle Velkerri B Shale.
- Drilling is expected to complete in 30 days, followed by a stimulation program using Liberty Energy's modern frac fleet.
- Initial flow test results are anticipated in Q1 2025, with production expected to start in H1 2026.
- The two-well program represents the largest campaign in the Beetaloo Basin to date.
- Tamboran Resources holds significant acreage and will use advanced US equipment to enhance the project's efficiency and performance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resonance Health Limited (RHT) ORDINARY FULLY PAID |
Health Care |
$18 |
Full Year Results Presentation
|
30 Aug 2024 9:34AM |
$0.062 |
$0.039 |
fallen by
37.10%
|
|
RHT - Price-sensitive ASX Announcement
Full Release
Key Points
- Resonance Health Limited reported its full-year financial results
- Revenue increased by 12% compared to the previous year
- Net loss decreased from $1.2 million to $0.8 million
- The company invested in research and development for new diagnostic technologies
- Regulatory approvals were obtained for HepaFat-Scan in multiple new regions
- Resonance Health expanded its global presence through partnerships and collaborations
- The company highlighted its focus on enhancing shareholder value through strategic initiatives
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Synertec Corporation Limited (SOP) ORDINARY FULLY PAID |
Industrials |
$16 |
Appendix 4G and Corporate Governance Statement
|
30 Aug 2024 9:34AM |
$0.075 |
$0.030 |
fallen by
60%
|
|
| Synertec Corporation Limited (SOP) ORDINARY FULLY PAID |
Industrials |
$16 |
Appendix 4E and 2024 Annual Report
|
30 Aug 2024 9:33AM |
$0.075 |
$0.030 |
fallen by
60%
|
|
SOP - Price-sensitive ASX Announcement
Full Release
Key Points
- Successful construction and deployment of two additional Powerhouse units with Santos
- Transformational capital restructure securing up to A$15 million in debt and a A$7 million share placement
- Profitable growth in Engineering division with $21.2 million in revenue
- Powerhouse technology recognized for improving operational efficiency, reducing fuel gas consumption, and cutting emissions
- Significant growth in the Engineering business, with $14 million in new contracts
- Strategic expansion with Powerhouse Grid Support product
- Strong revenue growth with $19.7 million in group revenue
- Completion of further Powerhouse systems contributing to commercial operations
- Positive safety performance with zero lost time injuries and Total Recordable Case Frequency Rate
- Continued focus on ESG initiatives and supporting social enterprises
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IODM Limited (IOD) ORDINARY FULLY PAID |
Information Technology |
$74 |
Appendix 4G Corporate Governance Statement
|
30 Aug 2024 9:32AM |
$0.175 |
$0.120 |
fallen by
31.43%
|
|
| Barrow Hanley Global Share Fund (Managed Fund) (GLOB) |
Financials |
$343 |
Quarterly Portfolio Disclosure - June 2024
|
30 Aug 2024 9:31AM |
$4.390 |
$5.020 |
risen by
14.35%
|
|
| Aerometrex Limited (AMX) ORDINARY FULLY PAID |
Industrials |
$21 |
FY24 Appendix 4E
|
30 Aug 2024 9:31AM |
$0.340 |
$0.220 |
fallen by
35.29%
|
|
AMX - Price-sensitive ASX Announcement
Full Release
Key Points
- Aerometrex Limited reported a net tangible asset backing per ordinary security of $0.15 for FY24, down from $0.22 in FY23.
- The company reported revenues from ordinary activities at $24,751,000 for FY24, a decrease of 2.4% from the previous year.
- Net loss from ordinary activities after tax attributable to members increased by 10.1% to $4,669,000 in FY24 compared to FY23.
- Aerometrex Limited did not propose or pay any dividends for the current year or the previous year.
- The company's financial statements for FY24 were audited by Grant Thornton Audit Pty Ltd.
- Operational highlights included no dividends paid or proposed, commentary on operational review, and compliance with Listing Rule 4.3A.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Perpetual Ethical SRI Fund (Managed Fund) (GIVE) |
Financials |
$13 |
Quarterly Portfolio Disclosure - June 2024
|
30 Aug 2024 9:30AM |
$3.130 |
$3.310 |
risen by
5.75%
|
|
| Tlou Energy Limited (TOU) ORDINARY FULLY PAID |
Energy |
$21 |
Application for quotation of securities - TOU
|
30 Aug 2024 9:30AM |
$0.034 |
$0.016 |
fallen by
52.94%
|
|
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$606 |
Update - Notification of buy-back - RF1
|
30 Aug 2024 9:29AM |
$3.190 |
$2.830 |
fallen by
11.29%
|
|
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$31 |
Appendix 4G and Corporate Governance Statement
|
30 Aug 2024 9:29AM |
$1.770 |
$0.275 |
fallen by
84.46%
|
|
| Tryptamine Therapeutics Limited (TYP) ORDINARY FULLY PAID |
Health Care |
$40 |
Appendix 4E Preliminary Final Report
|
30 Aug 2024 9:29AM |
$0.020 |
$0.029 |
risen by
45%
|
|
TYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from ordinary activities increased by 50493.6% to $985,057.
- Loss from ordinary activities after tax attributable to owners increased by 96.1% to $11,479,188.
- No dividends were paid, recommended, or declared during the current financial period.
- Acquisition of Tryp Therapeutics Inc and subsequent readmission to ASX.
- Net tangible assets per ordinary security improved to 0.44 cents from -4.65 cents.
- Company undertook a public offer of shares, raising $6,500,000.
- The financial statements reflect a 10-month period due to the change in accounting period.
- Significant increase in share-based payment expenses and transaction costs due to the reverse listing.
- Total expenses for the period were $12,464,245 compared to $5,856,585 in the previous period.
- Audit of the annual financial report is in process and not expected to be disputed or qualified.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$31 |
FY24 Results Announcement
|
30 Aug 2024 9:29AM |
$1.770 |
$0.275 |
fallen by
84.46%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma completed its IPO on December 11, 2023, raising AU$7 million.
- Company's shares commenced trading on the ASX under the ticker code ASX:LTP.
- As of June 30, 2024, LTR Pharma maintained a cash balance of $3.10 million.
- Completed a $10.5M placement to support key clinical and commercial milestones.
- Conducted a pivotal pharmacokinetic clinical study of SPONTAN nasal spray.
- SPONTAN showed rapid absorption and faster onset of action compared to oral PDE5 inhibitors.
- No serious adverse events were observed with SPONTAN.
- LTR Pharma completed critical manufacturing validation steps for SPONTAN.
- Secured a global Co-Development Agreement with Aptar Pharma to support SPONTAN's commercialization.
- SPONTAN prescribed under the TGA early access schemes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IODM Limited (IOD) ORDINARY FULLY PAID |
Information Technology |
$74 |
Appendix 4E Annual Report to shareholders
|
30 Aug 2024 9:29AM |
$0.175 |
$0.120 |
fallen by
31.43%
|
|
IOD - Price-sensitive ASX Announcement
Full Release
Key Points
- IODM limited operational revenue increased by 67% in FY2024 due to a commercial partnership with Convera.
- Revenue from the UK education sector saw a 195% increase from $366K in FY2023 to $1.08M in FY2024.
- A new revenue share agreement with Convera was implemented, providing IODM with 25% of all FX revenues from onboarded universities and 30% from new universities.
- The agreement guarantees a minimum payment of GBP150,000 per month to IODM.
- IODM raised $800,000 through a share placement on 11 March 2024 to enhance onboarding capabilities and augment sales and technical teams.
- The company incurred a net loss after tax of $3,105,765 in FY2024.
- IODM had a net cash outflow from operating activities of $2,442,258 in FY2024.
- The company executed significant onboarding of additional universities, especially in the UK education sector.
- IODM completed a share placement on 8 August 2024 raising $1,710,375.
- IOPM's board is undergoing transformation to ensure compliance and governance obligations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resonance Health Limited (RHT) ORDINARY FULLY PAID |
Health Care |
$18 |
Full Year Results
|
30 Aug 2024 9:29AM |
$0.052 |
$0.039 |
fallen by
25%
|
|
RHT - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $8.6M, an increase of 95% from the prior period
- Normalised EBITDA of $0.69M, up 183% from the prior period
- Net positive operating cashflow of $1.39M, an increase of 983% from the prior period
- Earnings Per Share (EPS) increased to 0.04 CPS
- New clinical trial invoiced $3.85M during the period with $2.48M balance to be invoiced in FY25
- Completed acquisition of TrialsWest with a new trial site opened in August 2024
- Received R&D tax rebate of $796K
- Net Cash position of $3.68M with $6.85M cash at bank
- Strong growth expected in FY25 from clinical trials and SaMD revenues
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 5G Networks Limited (5GN) ORDINARY FULLY PAID |
Information Technology |
$44 |
Notification of cessation of securities - 5GN
|
30 Aug 2024 9:28AM |
$0.150 |
$0.148 |
fallen by
1.67%
|
|
| Raiz Invest Limited (RZI) ORDINARY FULLY PAID |
Financials |
$62 |
Raiz Share Purchase Plan
|
30 Aug 2024 9:27AM |
$0.400 |
$0.588 |
risen by
46.88%
|
|
RZI - Price-sensitive ASX Announcement
Full Release
Key Points
- Raiz Invest Limited announced a Share Purchase Plan (SPP) to allow eligible shareholders to purchase up to $30,000 of new shares without incurring brokerage or other transaction costs.
- The SPP aims to raise up to $2 million and follows the successful institutional placements which raised $3 million.
- New SPP shares are offered at the lower of $0.41 per share or a 2.5% discount to the volume-weighted average price (VWAP) of Raiz Invest shares traded on ASX during the five trading days up to the SPP closing date.
- The proceeds from the SPP will be used for strategic opportunities, including building a bespoke AI language model, product innovation, and potential future mergers and acquisitions.
- Participation in the SPP is voluntary and is available to shareholders with addresses in Australia or New Zealand who held shares as of 23 August 2024.
- Shares issued under the SPP will rank equally with existing shares.
- The SPP is not available to shareholders in the United States or those holding shares on behalf of persons in the United States.
- Applications for the SPP must be received by 5:00pm on 13 September 2024, and shares will be issued on 20 September 2024.
- Raiz Invest reserves the right to scale back applications and any oversubscription funds will be refunded.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$31 |
Appendix 4E and Annual Financial Report
|
30 Aug 2024 9:27AM |
$1.770 |
$0.275 |
fallen by
84.46%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma Limited successfully completed an IPO and listed on the Australian Securities Exchange under the ticker ASX: LTP in December 2023.
- The company's flagship product, SPONTAN, is an innovative nasal spray treatment for Erectile Dysfunction (ED) designed to work within 10 minutes.
- SPONTAN has demonstrated a significant improvement over oral treatments in clinical studies, achieving maximum concentration levels in an average of 12 minutes.
- LTR Pharma's financial results for the year ended 30 June 2024 show a significant increase in revenue but also a substantial net loss.
- The company raised $7 million through its IPO to support R&D activities and the commercialisation pathway of SPONTAN.
- LTR Pharma completed its pivotal pharmacokinetic clinical study for SPONTAN, showing rapid absorption and faster onset of action compared to oral PDE5 inhibitors.
- The company achieved manufacturing validation for SPONTAN, meeting essential FDA requirements for a pivotal clinical study.
- LTR Pharma's Chief Scientific Advisor, Professor Eric Chung, was awarded the ISSM Emil Tanagho Prize for innovative research in ED treatments.
- The company's net tangible asset per ordinary share increased from 1.487 cents in 2023 to 2.109 cents in 2024.
- LTR Pharma completed a $10.5 million share placement and signed a Global Co-Development agreement post the financial year-end.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Livium Ltd (LIT) ORDINARY FULLY PAID |
Industrials |
$15 |
Sustainability Report
|
30 Aug 2024 9:26AM |
$0.021 |
$0.009 |
fallen by
57.14%
|
|
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$570 |
Appendix 4D and Financial Report
|
30 Aug 2024 9:25AM |
$1.330 |
$1.425 |
risen by
7.14%
|
|
FGG - Price-sensitive ASX Announcement
Full Release
Key Points
- True and fair view of the company’s financial position as at 30 June 2024.
- Compliance with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.
- Review conducted in accordance with ASRE 2410 Review of a Financial Report Performed by the Independent Auditor.
- Independence of the Company in accordance with the auditor independence requirements of the Corporations Act 2001.
- Directors are responsible for the preparation of the half-year financial report.
- Total comprehensive income for the period ended 30 June 2024.
- Financial performance overview includes trading revenue, cost of sales, gross profit, and other income and expenses.
- Balance sheet items cover working capital, property, plant and equipment, and provisions.
- Capital structure and risk management include credit facilities, issued capital, and financial risk management.
- Group structure details subsidiaries, deed of cross guarantee, and non-controlling interests.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
